Pegylated asparaginase as cause of fatal hyperammonemia in patients with latent urea cycle disorder

Pediatr Blood Cancer. 2018 Sep;65(9):e27239. doi: 10.1002/pbc.27239. Epub 2018 May 18.

Authors

Megan Peters¹, Janine Zee-Cheng², Ashley Kuhl³, Jennifer Orozco⁴, Everett Lally⁵, Jessica Scott Schwoerer¹

Affiliations

¹ Department of Pediatrics-Critical Care Medicine, University of Wisconsin, Madison, Wisconsin.
² Department of Pediatrics, Gundersen Health System, La Crosse, Wisconsin.
³ Department of Pediatrics-Medical Genetics, University of Wisconsin, Madison, Wisconsin.
⁴ Department of Pediatrics-Hematology & Oncology, Gundersen Health System, La Crosse, Wisconsin.
⁵ Department of Integrated Oncology and Genetics, ARUP Laboratories, Salt Lake City, Utah.

PMID: 29775236
DOI: 10.1002/pbc.27239

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adolescent
Asparaginase / adverse effects*
Asparaginase / therapeutic use
Brain Diseases, Metabolic / chemically induced*
Brain Edema / chemically induced
Delayed Diagnosis
Fatal Outcome
Humans
Hyperammonemia / chemically induced*
Male
Ornithine Carbamoyltransferase Deficiency Disease / complications*
Ornithine Carbamoyltransferase Deficiency Disease / diagnosis
Polyethylene Glycols / adverse effects*
Polyethylene Glycols / therapeutic use
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / complications
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*

Substances

Polyethylene Glycols
pegaspargase
Asparaginase